Stay tuned, leave your email
Articles récents
- Medincell announces successful c. €48 million Private Placement
- Medincell launches a private placement for international institutional investors
- Medincell to Participate in Leerink and Jefferies Miami Investor Conferences, March 8 – 11, 2026
- Medincell to Present at the TD Cowen 46th Annual Healthcare Conference in Boston, March 2-4, 2026
- U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Commentaires récents
No comments to show.
